ServiceNow (NYSE:NOW) Conference September 10, 2025 02:30 PM ET Company ParticipantsBill McDermott - Chairman & CEONoneGood morning, everybody. I'm Bill McDermott. Welcome back to your fourth Goldman Sachs MENA Copia conference. Thank you for being with us.Bill McDermottThank you for having me.NoneAppreciate it. Always, always good to talk with you. Let's just start straight in. We'll jump in. Outline for us a little bit about your long-term goals for ServiceNow. Talk about where the company is, and as you ...

Core Insights - Biotricity Inc. reported strong financial performance for Q1 of fiscal 2026, achieving a positive EBITDA for the first time, indicating a shift towards profitability and scalability of its business model [1][4][2] Financial Highlights - Revenue increased by 21% to $3.9 million compared to $3.2 million in Q4 FY24 [4] - Gross margin improved to 80.5% from 73.8% in the same quarter last year, driven by increased recurring technology fee revenue and operational efficiencies [4] - Net loss decreased significantly to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25, marking an 80.6% improvement [4] - Positive EBITDA of $333,337 was reported, an increase of 118.7% compared to the prior year quarter [4] - Recurring Technology Fees rose by 11.8% year-over-year to $3.4 million, also reflecting a 7.9% increase from the previous quarter [4] Operational Highlights - The company has established strategic alliances with three of the top Group Purchasing Organizations (GPOs), providing access to approximately 90% of all hospitals in the U.S. [2][4] - Biotricity is expanding its geographic footprint across 70% of the U.S., with penetration into thousands of physicians and hundreds of centers [4] - The company is working towards achieving regulatory approval in international markets, having already secured approvals in Canada, Saudi Arabia, and Argentina [4] Technological Advancements - The expansion of Biotricity's Cardiac AI Cloud platform is supported by partnerships with industry leaders, utilizing over 2 trillion beats of anonymized data to enhance diagnostic accuracy and clinic profitability [1][4] - The company continues to leverage AI technology and workflow automation to improve operational expenses, margins, and revenues [1]

Financial Performance - Underlying Revenue from customers reached $256.8 million, a 3.1% year-over-year increase[5] - Recurring Revenue accounted for $154.3 million of the Underlying Revenue[5] - Underlying Cash EBITDA was $43.8 million, resulting in a 17% Cash EBITDA margin[5] - The company ended the year with $58.7 million in cash and no debt[5] - A final FY25 dividend of $13.1 million (2.92c per share) and a special dividend of $8.0 million (1.79c per share) were distributed[5] Segment Performance - EMEA revenue was $186 million in FY25[12] - APAC revenue was $73 million in FY25[12] Future Outlook - The company expects FY26 revenues to be in line with FY25 and Cash EBITDA to be above $50 million[31] - One customer exit will impact FY26 revenue by A$10 million[37] Capital Allocation - A capital return of $73.2 million (16.3 cents per share) was paid in January 2025[28] - A special dividend of $40.0 million (8.92 cents per share) and 1H25 Dividend of $7.2 million (1.6 cents per share) was paid in April 2025[28]